Phase 2 Trial Highlights 100% Complete Response with Cilta-Cel in Smoldering Myeloma
During the 2024 ASH Annual Meeting and Exposition, findings from a single-arm phase 2 trial (NCT05767359) revealed that ciltacabtagene autoleucel (cilta-cel; Carvykti) induced a complete response (CR) in 100% of patients with high-risk smoldering multiple …